<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02957942</url>
  </required_header>
  <id_info>
    <org_study_id>PSYCH-2016-25008</org_study_id>
    <nct_id>NCT02957942</nct_id>
  </id_info>
  <brief_title>rTMS in Spasmodic Dysphonia</brief_title>
  <official_title>Repetitive Transcranial Magnetic Stimulation in Spasmodic Dysphonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Focal dystonia is a neurological movement disorder characterized by excessive involuntary&#xD;
      muscle contractions of any body part. Spasmodic dysphonia (SD) is a type of focal dystonia&#xD;
      characterized by excessive contraction of intrinsic muscles in the larynx, leading to&#xD;
      difficulty in speaking and affecting effective communication. The cause of SD is unknown and&#xD;
      there are no treatments that produce long-term benefits. Previous studies have suggested that&#xD;
      SD and other focal dystonias are associated with decreased inhibition in sensorimotor areas&#xD;
      in the brain. However, no studies have investigated the effects of modulating excitability of&#xD;
      the laryngeal motor cortex in healthy individuals or SD. The goal of this pilot project is to&#xD;
      determine if brain excitability of the laryngeal motor cortex can be changed with&#xD;
      low-frequency inhibitory repetitive transcranial magnetic stimulation (rTMS) in individuals&#xD;
      with SD and healthy controls. Considering that rTMS at low frequencies (â‰¤1 Hz) produces&#xD;
      lasting inhibition in the brain, and that SD is associated with decreased cortical&#xD;
      inhibition, the purpose of this pilot study is to determine safety, feasibility and response&#xD;
      to 1Hz rTMS to the laryngeal motor cortex in individuals with SD and healthy people. The&#xD;
      results will help understand changes associated with the disorder, as well as contribute to&#xD;
      the development of future clinical interventions for SD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Response to rTMS</measure>
    <time_frame>2.5 hours</time_frame>
    <description>Count of participants who experience and adverse response to rTMS treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Duration of Cortical Silent Period (CSP)</measure>
    <time_frame>baseline and 2.5 hours</time_frame>
    <description>The change from baseline in CSP duration will be reported. The CSP is an interruption of voluntary muscle contraction after single pulse transcranial stimulation. The duration of the period of silent muscle activity will be measured to test the effects of rTMS intervention. There is no known clinical relevance for this outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Voice Breaks</measure>
    <time_frame>baseline and 2.5 hours</time_frame>
    <description>Changes from baseline in the number of voice breaks during speech will be reported. Voice breaks will be measured by asking subjects to repeat 10 sentences. The frequency of voice breaks in the recorded 10 sentences will be counted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Voice Quality (Overall Severity) With the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)</measure>
    <time_frame>baseline and 2.5 hours</time_frame>
    <description>CAPE-V (overall severity) testing before and after rTMS consisted of the repetition of six sentences and two sustained vowels (/a/;/i/). A short sample of spontaneous speech (approximately 60s) was also collected for qualitative analysis of voice. The CAPE-V ratings were completed by three assessors who were blinded to group and pre/post-test. The assessors listened to the voice recordings for each participant and rated them for all six parameters listed above from 0 to 100, with higher values indicating worse severity. Ratings for each voice parameter were then averaged across the three assessors. We chose to analyze the change in the CAPE-V parameter for &quot;Overall Severity&quot; to represent an overall assessment of voice quality from pre- to post-rTMS (Post Score - Pre Score) as it had the greatest likelihood of detecting any small changes that may be perceived.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cepstral Peak Prominence Smoothed (CPPS)</measure>
    <time_frame>baseline and 2.5 hours</time_frame>
    <description>Quantitative assessment of voice quality was completed with acoustic analysis of each participant's production of the ten sentences from the Spasmodic Dysphonia Attribute Inventory (SDAI). A custom script in Praat (Boersma &amp; Weenink, 2018) was used to calculate cepstral peak prominence smoothed (CPPS) for each sentence production. CPPS is a relatively new measure that reflects vocal fold periodicity and noise components in the vocal spectrum. CPPS has been found to be correlated with perceived severity of voice symptoms and higher CPPS values represent a more normal vocal quality. CPPS values (in dB) were averaged across the ten sentences of the SDAI to derive an average CPPS for each participant before and after rTMS. Change for each participant was calculated as the average CPPS at post-rTMS minus average CPPS at pre-rTMS. The values for each group were then averaged to report the average change in CPPS for Controls and Spasmodic Dysphonia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Spasmodic Dysphonia</condition>
  <condition>Laryngeal Dystonia</condition>
  <arm_group>
    <arm_group_label>Spasmodic Dysphonia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1Hz repetitive transcranial magnetic stimulation (rTMS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy adults 1Hz repetitive transcranial magnetic stimulation (rTMS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>1Hz repetitive transcranial magnetic stimulation (rTMS)</intervention_name>
    <description>1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Spasmodic Dysphonia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary inclusion for spasmodic dysphonia:&#xD;
&#xD;
               1. Diagnosis of adductor spasmodic dysphonia&#xD;
&#xD;
               2. Symptoms at worst severity if receiving regular botulinum injections&#xD;
&#xD;
          -  Primary inclusion for healthy participants (controls):&#xD;
&#xD;
               1. Absence of vocal fold pathology&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary exclusion for participants with spasmodic dysphonia:&#xD;
&#xD;
               1. Other forms of dystonia&#xD;
&#xD;
               2. Vocal fold pathology or paralysis&#xD;
&#xD;
               3. Diagnosis of voice tremor&#xD;
&#xD;
               4. Laryngeal surgery&#xD;
&#xD;
               5. Laryngeal cancer or neurological condition other than dystonia&#xD;
&#xD;
               6. Contraindication to TMS&#xD;
&#xD;
               7. Medications with effect on central nervous system&#xD;
&#xD;
               8. Inability to complete tasks associated with study&#xD;
&#xD;
               9. Adult lacking ability to consent&#xD;
&#xD;
          -  Primary exclusion for healthy participants (controls):&#xD;
&#xD;
               1. Any health condition or disability that would interfere with participation&#xD;
&#xD;
               2. Contraindications to TMS&#xD;
&#xD;
               3. Medications with effect on central nervous system&#xD;
&#xD;
               4. Adult lacking ability to consent&#xD;
&#xD;
        TMS contraindications:&#xD;
&#xD;
          -  The only absolute contraindication to TMS/rTMS is the presence of metallic hardware in&#xD;
             close contact to the discharging coil (such as cochlear implants, deep brain&#xD;
             stimulator, or medication pumps). In such instances there is a risk of inducing&#xD;
             malfunctioning of the implanted devices.&#xD;
&#xD;
          -  Conditions classified as of increased or uncertain risk are listed below (Rossi et&#xD;
             al., 2009; Rossini et al., 2015). Persons under those circumstances will be excluded&#xD;
             from the study.&#xD;
&#xD;
               1. Pregnancy&#xD;
&#xD;
               2. Bipolar disorder&#xD;
&#xD;
               3. Epilepsy or history of seizure episodes in the past two years&#xD;
&#xD;
               4. Vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, even&#xD;
                  without history of seizure, and without anticonvulsant medication&#xD;
&#xD;
               5. Use of medications that potentially lower seizure threshold&#xD;
&#xD;
               6. Severe or recent heart disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mo Chen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresa J Kimberley, PhD, PT</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Noninvasive Neuromodulation Laboratory</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rossi S, Hallett M, Rossini PM, Pascual-Leone A; Safety of TMS Consensus Group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009 Dec;120(12):2008-2039. doi: 10.1016/j.clinph.2009.08.016. Epub 2009 Oct 14. Review.</citation>
    <PMID>19833552</PMID>
  </reference>
  <reference>
    <citation>Rossini PM, Burke D, Chen R, Cohen LG, Daskalakis Z, Di Iorio R, Di Lazzaro V, Ferreri F, Fitzgerald PB, George MS, Hallett M, Lefaucheur JP, Langguth B, Matsumoto H, Miniussi C, Nitsche MA, Pascual-Leone A, Paulus W, Rossi S, Rothwell JC, Siebner HR, Ugawa Y, Walsh V, Ziemann U. Non-invasive electrical and magnetic stimulation of the brain, spinal cord, roots and peripheral nerves: Basic principles and procedures for routine clinical and research application. An updated report from an I.F.C.N. Committee. Clin Neurophysiol. 2015 Jun;126(6):1071-1107. doi: 10.1016/j.clinph.2015.02.001. Epub 2015 Feb 10. Review.</citation>
    <PMID>25797650</PMID>
  </reference>
  <reference>
    <citation>Summers RL, Chen M, Kimberley TJ. Corticospinal excitability measurements using transcranial magnetic stimulation are valid with intramuscular electromyography. PLoS One. 2017 Feb 23;12(2):e0172152. doi: 10.1371/journal.pone.0172152. eCollection 2017.</citation>
    <PMID>28231250</PMID>
  </reference>
  <reference>
    <citation>Kimberley TJ, Schmidt RL, Chen M, Dykstra DD, Buetefisch CM. Mixed effectiveness of rTMS and retraining in the treatment of focal hand dystonia. Front Hum Neurosci. 2015 Jul 9;9:385. doi: 10.3389/fnhum.2015.00385. eCollection 2015.</citation>
    <PMID>26217209</PMID>
  </reference>
  <reference>
    <citation>Chen M, Summers RL, Goding GS, Samargia S, Ludlow CL, Prudente CN, Kimberley TJ. Evaluation of the Cortical Silent Period of the Laryngeal Motor Cortex in Healthy Individuals. Front Neurosci. 2017 Mar 7;11:88. doi: 10.3389/fnins.2017.00088. eCollection 2017.</citation>
    <PMID>28326007</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>November 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2016</study_first_posted>
  <results_first_submitted>September 2, 2020</results_first_submitted>
  <results_first_submitted_qc>September 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 1, 2020</results_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Repetitive transcranial magnetic stimulation (rTMS)</keyword>
  <keyword>Spasmodic dysphonia</keyword>
  <keyword>Dystonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysphonia</mesh_term>
    <mesh_term>Hoarseness</mesh_term>
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT02957942/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Spasmodic Dysphonia</title>
          <description>1Hz repetitive transcranial magnetic stimulation (rTMS)&#xD;
1Hz repetitive transcranial magnetic stimulation (rTMS): 1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)</description>
        </group>
        <group group_id="P2">
          <title>Healthy Control</title>
          <description>Healthy adults 1Hz repetitive transcranial magnetic stimulation (rTMS)&#xD;
1Hz repetitive transcranial magnetic stimulation (rTMS): 1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="13">7 healthy individuals were recruited as control; 6 were recruited for practicing experiment details.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Practicing experiment protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Spasmodic Dysphonia</title>
          <description>1Hz repetitive transcranial magnetic stimulation (rTMS)&#xD;
1Hz repetitive transcranial magnetic stimulation (rTMS): 1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)</description>
        </group>
        <group group_id="B2">
          <title>Healthy Control</title>
          <description>Healthy adults 1Hz repetitive transcranial magnetic stimulation (rTMS)&#xD;
1Hz repetitive transcranial magnetic stimulation (rTMS): 1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="3.8"/>
                    <measurement group_id="B2" value="53.2" spread="6.6"/>
                    <measurement group_id="B3" value="57.4" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Response to rTMS</title>
        <description>Count of participants who experience and adverse response to rTMS treatment.</description>
        <time_frame>2.5 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Spasmodic Dysphonia</title>
            <description>1Hz repetitive transcranial magnetic stimulation (rTMS)&#xD;
1Hz repetitive transcranial magnetic stimulation (rTMS): 1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control</title>
            <description>Healthy adults 1Hz repetitive transcranial magnetic stimulation (rTMS)&#xD;
1Hz repetitive transcranial magnetic stimulation (rTMS): 1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Response to rTMS</title>
          <description>Count of participants who experience and adverse response to rTMS treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Duration of Cortical Silent Period (CSP)</title>
        <description>The change from baseline in CSP duration will be reported. The CSP is an interruption of voluntary muscle contraction after single pulse transcranial stimulation. The duration of the period of silent muscle activity will be measured to test the effects of rTMS intervention. There is no known clinical relevance for this outcome measure.</description>
        <time_frame>baseline and 2.5 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Spasmodic Dysphonia</title>
            <description>1Hz repetitive transcranial magnetic stimulation (rTMS)&#xD;
1Hz repetitive transcranial magnetic stimulation (rTMS): 1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control</title>
            <description>Healthy adults 1Hz repetitive transcranial magnetic stimulation (rTMS)&#xD;
1Hz repetitive transcranial magnetic stimulation (rTMS): 1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Duration of Cortical Silent Period (CSP)</title>
          <description>The change from baseline in CSP duration will be reported. The CSP is an interruption of voluntary muscle contraction after single pulse transcranial stimulation. The duration of the period of silent muscle activity will be measured to test the effects of rTMS intervention. There is no known clinical relevance for this outcome measure.</description>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="10.6"/>
                    <measurement group_id="O2" value="3.6" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Voice Breaks</title>
        <description>Changes from baseline in the number of voice breaks during speech will be reported. Voice breaks will be measured by asking subjects to repeat 10 sentences. The frequency of voice breaks in the recorded 10 sentences will be counted.</description>
        <time_frame>baseline and 2.5 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Spasmodic Dysphonia</title>
            <description>1Hz repetitive transcranial magnetic stimulation (rTMS)&#xD;
1Hz repetitive transcranial magnetic stimulation (rTMS): 1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control</title>
            <description>Healthy adults 1Hz repetitive transcranial magnetic stimulation (rTMS)&#xD;
1Hz repetitive transcranial magnetic stimulation (rTMS): 1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Voice Breaks</title>
          <description>Changes from baseline in the number of voice breaks during speech will be reported. Voice breaks will be measured by asking subjects to repeat 10 sentences. The frequency of voice breaks in the recorded 10 sentences will be counted.</description>
          <units>total voice breaks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="4.7"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Voice Quality (Overall Severity) With the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)</title>
        <description>CAPE-V (overall severity) testing before and after rTMS consisted of the repetition of six sentences and two sustained vowels (/a/;/i/). A short sample of spontaneous speech (approximately 60s) was also collected for qualitative analysis of voice. The CAPE-V ratings were completed by three assessors who were blinded to group and pre/post-test. The assessors listened to the voice recordings for each participant and rated them for all six parameters listed above from 0 to 100, with higher values indicating worse severity. Ratings for each voice parameter were then averaged across the three assessors. We chose to analyze the change in the CAPE-V parameter for &quot;Overall Severity&quot; to represent an overall assessment of voice quality from pre- to post-rTMS (Post Score - Pre Score) as it had the greatest likelihood of detecting any small changes that may be perceived.</description>
        <time_frame>baseline and 2.5 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Spasmodic Dysphonia</title>
            <description>1Hz repetitive transcranial magnetic stimulation (rTMS)&#xD;
1Hz repetitive transcranial magnetic stimulation (rTMS): 1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control</title>
            <description>Healthy adults 1Hz repetitive transcranial magnetic stimulation (rTMS)&#xD;
1Hz repetitive transcranial magnetic stimulation (rTMS): 1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Voice Quality (Overall Severity) With the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)</title>
          <description>CAPE-V (overall severity) testing before and after rTMS consisted of the repetition of six sentences and two sustained vowels (/a/;/i/). A short sample of spontaneous speech (approximately 60s) was also collected for qualitative analysis of voice. The CAPE-V ratings were completed by three assessors who were blinded to group and pre/post-test. The assessors listened to the voice recordings for each participant and rated them for all six parameters listed above from 0 to 100, with higher values indicating worse severity. Ratings for each voice parameter were then averaged across the three assessors. We chose to analyze the change in the CAPE-V parameter for &quot;Overall Severity&quot; to represent an overall assessment of voice quality from pre- to post-rTMS (Post Score - Pre Score) as it had the greatest likelihood of detecting any small changes that may be perceived.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="10.5"/>
                    <measurement group_id="O2" value="0.9" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cepstral Peak Prominence Smoothed (CPPS)</title>
        <description>Quantitative assessment of voice quality was completed with acoustic analysis of each participant's production of the ten sentences from the Spasmodic Dysphonia Attribute Inventory (SDAI). A custom script in Praat (Boersma &amp; Weenink, 2018) was used to calculate cepstral peak prominence smoothed (CPPS) for each sentence production. CPPS is a relatively new measure that reflects vocal fold periodicity and noise components in the vocal spectrum. CPPS has been found to be correlated with perceived severity of voice symptoms and higher CPPS values represent a more normal vocal quality. CPPS values (in dB) were averaged across the ten sentences of the SDAI to derive an average CPPS for each participant before and after rTMS. Change for each participant was calculated as the average CPPS at post-rTMS minus average CPPS at pre-rTMS. The values for each group were then averaged to report the average change in CPPS for Controls and Spasmodic Dysphonia.</description>
        <time_frame>baseline and 2.5 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Spasmodic Dysphonia</title>
            <description>1Hz repetitive transcranial magnetic stimulation (rTMS)&#xD;
1Hz repetitive transcranial magnetic stimulation (rTMS): 1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control</title>
            <description>Healthy adults 1Hz repetitive transcranial magnetic stimulation (rTMS)&#xD;
1Hz repetitive transcranial magnetic stimulation (rTMS): 1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cepstral Peak Prominence Smoothed (CPPS)</title>
          <description>Quantitative assessment of voice quality was completed with acoustic analysis of each participant's production of the ten sentences from the Spasmodic Dysphonia Attribute Inventory (SDAI). A custom script in Praat (Boersma &amp; Weenink, 2018) was used to calculate cepstral peak prominence smoothed (CPPS) for each sentence production. CPPS is a relatively new measure that reflects vocal fold periodicity and noise components in the vocal spectrum. CPPS has been found to be correlated with perceived severity of voice symptoms and higher CPPS values represent a more normal vocal quality. CPPS values (in dB) were averaged across the ten sentences of the SDAI to derive an average CPPS for each participant before and after rTMS. Change for each participant was calculated as the average CPPS at post-rTMS minus average CPPS at pre-rTMS. The values for each group were then averaged to report the average change in CPPS for Controls and Spasmodic Dysphonia.</description>
          <units>dB</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.7"/>
                    <measurement group_id="O2" value="0.3" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Spasmodic Dysphonia</title>
          <description>1Hz repetitive transcranial magnetic stimulation (rTMS)&#xD;
1Hz repetitive transcranial magnetic stimulation (rTMS): 1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)</description>
        </group>
        <group group_id="E2">
          <title>Healthy Control</title>
          <description>Healthy adults 1Hz repetitive transcranial magnetic stimulation (rTMS)&#xD;
1Hz repetitive transcranial magnetic stimulation (rTMS): 1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dental Pain/Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Other(fatigue)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tenderness on Skin Area of Insertion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mo Chen</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-624-5220</phone>
      <email>mchen@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

